Vaxcyte Inc. | Mid-cap | Healthcare
$32.00
-3.76%
| Vaxcyte Stock Comparison:
Vaxcyte vs VertexVaxcyte vs RegeneronVaxcyte vs Blueprint MedicinesVaxcyte vs Roivant SciencesVaxcyte vs Bio-TechneVaxcyte vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 0
Operating Income -569.5M
Net Income -463.9M
EPS (Diluted) -$3.80

Balance Sheet Metrics

Total Assets 3.5B
Total Liabilities 205.5M
Shareholders Equity 3.3B
Debt to Equity 0.06

Cash Flow Metrics

Operating Cash Flow -392.4M
Free Cash Flow -571.8M

Revenue & Profitability Trend

Vaxcyte Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue00000
Cost of Goods Sold-----
Gross Profit-----
Operating Expenses569.5M388.3M207.3M102.1M87.1M
Operating Income-569.5M-388.3M-207.3M-102.1M-87.1M
Pre-tax Income-463.9M-402.3M-223.5M-100.1M-89.2M
Income Tax-----
Net Income-463.9M-402.3M-223.5M-100.1M-89.2M
EPS (Diluted)-$3.80-$4.14-$3.44-$1.93-$3.02

Income Statement Trend

Vaxcyte Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.8B1.1B942.6M256.3M389.0M
Non-Current Assets1.7B312.0M63.6M68.0M3.8M
Total Assets3.5B1.4B1.0B324.3M392.8M
Liabilities
Current Liabilities140.2M145.3M40.5M28.7M46.9M
Non-Current Liabilities65.3M22.1M12.0M11.6M122.0K
Total Liabilities205.5M167.4M52.6M40.3M47.0M
Equity
Total Shareholders Equity3.3B1.2B953.6M284.0M345.8M

Balance Sheet Composition

Vaxcyte Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-463.9M-402.3M-223.5M-100.1M-89.2M
Operating Cash Flow-392.4M-360.7M-181.3M-111.6M-56.3M
Investing Activities
Capital Expenditures-119.2M-67.9M-5.8M-6.5M-1.1M
Investing Cash Flow-2.0B-773.3M74.6M-212.3M-1.1M
Financing Activities
Dividends Paid-----
Financing Cash Flow2.4B632.2M855.6M13.9M370.5M
Free Cash Flow-571.8M-364.7M-176.4M-127.9M-47.8M

Cash Flow Trend

Vaxcyte Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -8.97
Forward P/E -7.24
Price to Book 1.37
PEG Ratio -7.24

Profitability Ratios

Profit Margin 0.00%
Operating Margin 0.00%
Return on Equity -19.66%
Return on Assets -14.53%

Financial Health

Current Ratio 17.70
Debt to Equity 2.73
Beta 1.20

Per Share Data

EPS (TTM) -$3.99
Book Value per Share $24.82
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
pcvx4.4B-8.971.37-19.66%0.00%2.73
Vertex 114.1B32.826.92-5.64%-8.91%10.00
Regeneron 55.3B13.021.8415.96%31.94%9.20
Blueprint Medicines 8.3B-120.0024.19-47.71%-27.70%208.50
Roivant Sciences 7.8B1.951.71-12.54%96.86%1.93
Bio-Techne 7.9B60.873.926.53%10.89%20.99

Financial data is updated regularly. All figures are in the company's reporting currency.